Personalis (PSNL) Q2 Revenue Falls 24%

Personalis (NASDAQ:PSNL), a precision genomics company focused on ultra-sensitive minimal residual disease (MRD) detection and comprehensive tumor profiling for cancer, reported its second-quarter 2025 results on August 5, 2025. The main headline was a significant shortfall in revenue, which came in at $17.2 million (GAAP), versus analysts’ estimate of $20.1 million, a 24.0% drop from Q2 2024. Earnings per share (EPS) registered a loss of $0.23 (GAAP), slightly better than the $0.24 GAAP loss per share expected, but net losses (GAAP) widened in absolute terms. The period saw a sharp drop in gross margin to 27.6%, falloff of legacy customer revenue, and a downward revision to full-year revenue and gross margin outlooks. Despite these financial pressures, the company posted rapid increases in clinical test adoption, with a 59% sequential increase in clinical test volume, reflecting traction for its key platform, NeXT Personal. Overall, the quarter showed strong operational momentum in the clinic, but was overshadowed by persistent financial challenges and deepening losses. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Personalis develops and commercializes testing products for cancer, specializing in genomic analysis for minimal residual disease and tumor profiling. Its flagship product line, NeXT Personal, is an ultra-sensitive MRD test designed to detect early recurrences of cancer using blood samples. The company’s ImmunoID NeXT offering delivers a detailed tumor and immune profiling service, primarily used by biopharma companies for therapy development.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool